Sarepta Therapeutics (SRPT) Gains Ahead of FDA Decision
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) is seeing strong upside Wednesday as investors continue to wait for an FDA decision on eteplirsen, which some still expect to come this month. Shares are up 6.5%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Shares Slip 0.8% Early
- Autozone (AZO) December weekly volatility at 31 into Q1 and outlook
- Options with increasing volume: ABY NKTR PEIX SPA NVS RUTH AIRM BTI NBR